Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mind Medicine (MindMed) Inc. - Common Shares
(NQ:
MNMD
)
6.600
+0.050 (+0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine (MindMed) Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
From
MindMed
Via
Business Wire
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...
Via
Benzinga
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
August 03, 2023
From
Mind Medicine (MindMed) Inc
Via
Business Wire
Mind Science Targeting Big Brains and Portfolios
August 02, 2023
Via
AB Newswire
The Latest Analyst Ratings for Mind Medicine
June 28, 2023
Via
Benzinga
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
July 31, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average
July 30, 2023
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July:
Via
Talk Markets
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
July 28, 2023
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:
Via
Benzinga
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
July 26, 2023
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END
Via
FinancialNewsMedia
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD
July 23, 2023
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug...
Via
Talk Markets
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 18, 2023
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.
Via
Benzinga
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD
July 14, 2023
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD.
Via
Talk Markets
Psychedelic Stocks Jumped 10% Last Week
July 09, 2023
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly
Via
Talk Markets
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues
July 01, 2023
Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up...
Via
Talk Markets
The 3 Best Psychedelic Stocks to Buy Now
June 29, 2023
Psychedelic stocks promise to bring therapeutics to market that were taboo until recently and have huge upside.
Via
InvestorPlace
MindMed Shareholders Vote For All Six Company Nominees At Annual Meeting, Current R&D Path Upheld
June 27, 2023
MindMed’s (NASDAQ: MNMD) heated proxy battle over R&D strategy might finally be coming to an end.
Via
Benzinga
FCM Received Significant Support from Shareholders, Disappointed that “Passive” Investors Saw Fit to Give Incumbent Directors Another Chance to Disappoint
June 22, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
June 22, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Announces Election of All Six Company Nominees at Annual Meeting
June 21, 2023
From
Mind Medicine
Via
Business Wire
MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day
June 20, 2023
From
Mind Medicine
Via
Business Wire
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue
June 17, 2023
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD.
Via
Talk Markets
FCM Denounces MindMed’s Manipulation of Corporate Machinery to Protect Incumbent Board of Directors
June 15, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
MindMed Adjourns Annual General Meeting of Shareholders
June 15, 2023
From
Mind Medicine
Via
Business Wire
Major Psychedelic Compound-Based Research & Development Stocks: June Update
June 10, 2023
Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index
Via
Talk Markets
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
June 09, 2023
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr.
Via
Benzinga
MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline
June 09, 2023
From
MindMed
Via
Business Wire
Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees
June 08, 2023
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
June 07, 2023
From
Concerned Shareholders of Company MindMed
Via
GlobeNewswire
MindMed to Host Investor Day June 2023
June 07, 2023
From
Mind Medicine
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.